

References

I-32

1. Casale R, Mattia C. Building a diagnostic algorithm on localized neuropathic pain (LNP) and targeted topical treatment: focus on 5% lidocaine-medicated plaster. *Therapeutics and Clinical Risk Management*. 2014;10:259-268.
2. Martinez V, Attal N, Vanzo B, et al. Adherence of french GPs to chronic neuropathic pain clinical guidelines: results of a cross-sectional, randomized, “e” case-vignette survey. *PlosOne*. 2014;9(4):e93855.
3. Kurdi M, Theerth K, Deva R. Ketamine: Current applications in anesthesia, pain, and critical care. *Anesthesia Essays and Researches*. 2014;8(3):283–290.
4. Souza M, Kraychete D. The analgesic effect of intravenous lidocaine in the treatment of chronic pain: A literature review. *Revista Brasileira De Reumatologia*. 2014;54(5):386–392.
5. Przeklasa-Muszynska A, Kocot-Kepska M, Dobrogowski J, et al. Intravenous lidocaine infusions in a multidirectional model of treatment of neuropathic pain patients. *Pharmacological Reports*. 2016;68(5):1069-1075.
6. Hutson P, Backonja M, Knurr H. Intravenous Lidocaine for Neuropathic Pain: A Retrospective Analysis of Tolerability and Efficacy. *Pain Medicine*. 2015; 68(5)531-536.
7. Ferreira de Souza M, Kraychete DC. The analgesic effect of intravenous lidocaine in the treatment of chronic pain: a literature review. *Rev Bras Reumatol*. 2014;54(5)386-392.
8. Van der Wal SEI, van den Heuvel SAS, Radema SA, et al. The in vitro mechanisms and in vivo efficacy of intravenous lidocaine on the neuroinflammatory response in acute and chronic pain. *Eur J Pain*. 2016;20(5):655-674.
9. Hayes, Inc. Hayes Medical Technology Directory Report. Intravenous Lidocaine Infusion for Neuropathic Pain: A Review of Reviews. Lansdale, PA: Hayes, Inc.; Apr, 2017.

10. Hayes, Inc. Hayes Medical Technology Directory Report. Intravenous Ketamine for Chronic Nonmalignant Pain. Lansdale, PA: Hayes, Inc.; Apr, 2017.
11. Vadivelu N, Schermer E, Kodumudi V, et al. Role of ketamine for analgesia in adults and children. *Journal of Anaesthesiology Clinical Pharmacology*. 2016;32(3):298-306..
12. MICROMEDEX®SOLUTIONS Compendia. 2020. Lidocaine Hydrochloride.
13. MICROMEDEX®SOLUTIONS Compendia. 2020. Ketamine Hydrochloride.
14. Kim YC, Castaneda AM, Lee CS, et al. Efficacy and safety of lidocaine infusion treatment for neuropathic pain: a randomized, doubleblind, and placebo-controlled study. *Reg Anesth Pain Med*. May 2018;43(4):415-424. PMID 29381569
15. Przeklasa-Muszynska A, Kocot-Kepska M, Dobrogowski J, et al. Intravenous lidocaine infusions in a multidirectional model of treatment of neuropathic pain patients. *Pharmacol Rep*. Oct 2016;68(5):1069-1075. PMID 27552062
16. Motov S, Mai M, Pushkar I, et al. A prospective randomized, double-dummy trial comparing IV push low dose ketamine to short infusion of low dose ketamine for treatment of pain in the ED. *Am J Emerg Med*. Aug 2017;35(8):1095-1100.
17. Hayes, Inc. Hayes Medical Technology Directory. Ketamine as Primary Therapy for Treatment-Resistant Unipolar Depression or Posttraumatic Stress Disorder. Lansdale, PA: Hayes, Inc.; 2017.